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ABSTRACT AND KEYWORDS 
Background: Soluble mesothelin-related peptide (SMRP) is a promising diagnostic biomarker for 
malignant pleural mesothelioma (MPM), but various confounders hinder its usefulness in surveillance 
programmes. We previously showed that a single nucleotide polymorphism (SNP) within the 
3’untranslated region (3’UTR) of the mesothelin (MSLN) gene could affect the levels of SMRP. 
Objectives To focus on SNPs located within MSLN promoter as possible critical genetic variables 
in determining SMRP levels. 
Methods: The association between SMRP and SNPs was tested in 689 non-MPM subjects and 70 
patients with MPM. Reporter plasmids carrying the four most common haplotypes were compared in 
a dual luciferase assay, and in silico analyses were performed to investigate the putative biological 
role of the SNPs. 
Results: We found a strong association between serum SMRP and variant alleles of rs3764247, 
rs3764246 (in strong linkage disequilibrium with rs2235504) and rs2235503 in non-MPM subjects. 
Inclusion of the genotype information led to an increase in SMRP specificity from 79.9% to 85.5%. 
Although not statistically significant, the group with MPM showed the same trend of association. 
According to the in vitro luciferase study, rs3764247 itself had a functional role. In silico approaches 
showed that the binding sites for transcription factors such as Staf and ZNF143 could be affected by 
this SNP. The other SNPs were shown to interact with each other in a more complex way. 
Conclusions: These data support the suggestion that SMRP performance is affected by individual 
(ie, genetic) variables and that MSLN expression is influenced by SNPs located within the promoter 
regulatory region. 
KEY WORDS: mesothelioma, polymorphisms, health surveillance 
 
 
 
 
INTRODUCTION 
Mesothelin (MSLN) is a membrane-bound glycoprotein physiologically expressed by the mesothelial 
tissues of pleura, peritoneum and pericardium.1 Although its biological function is still unknown,2 
many types of cancer, including malignant pleural mesothelioma (MPM), show increased expression 
of MSLN compared with their non-malignant counterparts.3 MPM is a highly aggressive tumour of 
the pleural cavities, associated with asbestos exposure and characterised by challenging diagnosis and 
poor prognosis.4 In recent years, several research groups have suggested that MSLN might be helpful 
in the management of MPM, both as a diagnostic tool5 6 and as a putative therapeutic target.7 8 In 
particular, high levels of the soluble form of MSLN, the so-called SMRP (soluble mesothelin-related 
peptides), were repeatedly found in serum samples of patients with MPM in comparison with various 
types of control groups.6 9 10 Nonetheless, in spite of the initial findings, the real usefulness of SMRP 
within surveillance programmes is hindered by a relatively high rate of false-negative and false-posi-
tive results.11 Various demographic and clinical variables were reported as possible confounders, 
such as body mass index, age, glomerular filtration rate and lung function.12–14 Genetic factors were 
also shown to affect SMRP levels in non-MPM subjects. Thus, the inclusion of individuals’ genetic 
information could improve the receiver operating characteristic (ROC) curves, leading to slight 
improvement of the performance of SMRP as biomarker.15 
Previously, studying a broad cohort of non-MPM subjects, we reported an association between serum 
SMRP levels and rs1057147, a single nucleotide polymorphism (SNP) located within the 
3’untranslated region (3’UTR) of MSLN. This SNP lies within the binding site for miR-611, thereby 
affecting the post-transcriptional regulation of MSLN mRNA.15 Similarly, genetic variants located 
within the promoter region of MSLN were found to be associated with SMRP levels in a small group 
of non-MPM volunteers.16 Healthy subjects carrying the variant allele of rs3764247 A>C (reported 
as New1 in the original publication) showed increased SMRP levels compared with those carrying 
the AA genotype.16 This could be ascribed to a different regulatory pattern depending on the presence 
of the variant or common allele. In this present study we analysed a large sample set and were able 
to replicate the association between rs3764247 and SMRP levels. Moreover, in order to further 
explore the role of genetic variants in MSLN/SMRP regulation, we (i) evaluated the association 
between SMRP and other SNPs located within the proximal MSLN promoter and (ii) performed an 
in vitro study to assess the biological role of the selected SNPs. These findings could help to refine 
the use of SMRP as diagnostic biomarker and shed some light on the regulatory mechanisms of the 
MSLN gene. 
 
MATERIALS AND METHODS 
Selection of SNPs  
In the pilot study, an association between rs3764247 and SMRP was found.16 Here the association 
analysis was extended to other SNPs lying within the region of the proximal promoter of MSLN. 
Thus, selection criteria for the SNPs were (i) they must lie within 1000 bp (arbitrarily chosen) 
upstream of the MSLN transcriptional start site (TSS); (ii) the frequency of the rare allele must exceed 
>0.05; (iii) they must be reported as associated with MSLN mRNA expression in 278 lung tissue 
samples according to GTex portal (http://www. gtexportal. org/ home/).17 The linkage disequilibrium 
(LD) between the selected SNPs (ie, rs3764247 A>C, rs3764246 A>G, rs2235503 C>A, rs2235504 
A>G) and the most common haplotypes was estimated with HaploView software version 4.2 
(https://www. broadinstitute. org/ haploview/ haploview) using the TSI (Tuscans in Italy) population 
(however, CEU (Northern Europeans from Utah) samples gave overlapping results). 
Population description and genotyping  
A total of 689 non-MPM subjects (healthy individuals n=371, or patients affected by benign 
respiratory diseases (BRDs), n=318) and 70 MPM volunteers were recruited at the University 
Hospital of Pisa as part of an occupational surveillance programme on workers previously exposed 
to asbestos, as described in detail by Garritano et al.15 Table 1 shows the clinical and demographic 
characteristics of the sample set.  
The study was approved by the institutional ethical committee of the University Hospital of Pisa. All 
subjects provided written informed consent. For genotyping, whole blood and serum samples were 
obtained by venepuncture and kept at −80°C until examination. DNA was extracted from whole blood 
samples using EuroGOLD Blood DNA Mini Kit (EuroClone, Pero, Italy). Genotyping of the three 
selected SNPs (ie, rs3764247, rs3764246 and rs2235503) was performed using KASPar PCR SNP 
genotyping system (LGC Genomics Ltd, Teddington, Middlesex, UK) with a success rate >96%. 
Allele frequencies (shown in table 1) were in agreement with those reported in HapMap project for 
TSI (0.20, 0.25 and 0.15 for rs3764247, rs3764246 and rs2235503, respectively) and followed the 
Hardy–Weinberg equilibrium (p=0.753, p=0.583 and p=0.625, respectively). 
Serum SMRP levels were measured using an enzyme-linked immunosorbent assay according to the 
manufacturer’s instructions (Mesomark, Fujirebio Diagnostics, Japan). 
 
 Healthy BRD MPM 
Sex    
Male 97.8% (363) 98.4% (313) 85.7% (60) 
Female 2.2% (8) 1.6% (5) 14.3% (10) 
Age (years)    
Average 58.9±13.5 65.8±10.7 70.5±10.8 
Median 60 66 71 
Smoking    
Smokers 16.2% (60) 16.2% (51) 8.3% (6) 
Ex-Smokers 39.9% (148) 54.0% (172) 58.3% (41) 
Non-Smokers 43.9% (163) 29.8% (95) 33.4% (23) 
Asbestos exposure (years)    
Average 15.6±11.5 20.0±10.7 23.2±19.1 
Median 15 20 25 
Diagnosis    
  *Pleural 56.5% (180) eMPM 60.0% (42) 
  **Lung 35% (111) sMPM 21.4% (15) 
  ***Airways 8.5% (27) bMPM 18.6% (13) 
MAF    
rs3764247 (C) 0.20 0.18 0.20 
rs3764246 (G) 0.24 0.22 0.25 
rs2235503 (A) 0.15 0.13 0.16 
Total 371 318 70 
Legend: *Pleural diseases include: pleural plaques 30.8% (98), pleural thickening 20.1% (64), pleural effusion 1.9% (6), 
pleuritis 3.7% (12). **Lung diseases include emphysema 10.1% (32), lung fibrosis 4.1% (13), nodules 15.1% (48), 
asbestosis 5.7% (18). ***Airways diseases correspond to bronchiectasis 8.5% (27). BRD Benign Respiratory Disease. 
eMPM Epithelioid Malignant Pleural Mesothelioma; sMPM Sarcomatoid Malignant Pleural Mesothelioma; bMPM 
Biphasic Mesothelioma. MAF= minor allele frequency; the minor allele for each SNP is reported in brackets. 
 
 
Association analyses between genotypes and SMRP levels 
To verify the association between genotypes and serum SMRP levels, one-way analysis of variance 
(ANOVA) was performed, stratified for health status (healthy, BRD, MPM), for each SNP. 
Tukey’s multiple comparison tests were performed to assess pairwise differences between the three 
genotypes within each group. In order to ascertain the global role of these SNPs in the association 
with SMRP in the different diagnostic groups, both the ‘non-MPM’ (healthy subjects + patients with 
BRD) and the MPM groups were stratified according to a three-SNPs classifier. 
According to this classifier, individuals carrying the common homozygote genotype for all the SNPs 
were considered as the reference category and were referred as carriers of the ‘L genotype’ (L=low 
expression), whereas all the remaining subjects (ie, carriers of at least one variant allele in one of the 
three SNPs) were considered to carry the ‘H genotype’ (H=high). Then, a multivariate analysis of 
variance (mANOVA) was carried out to assess the association between SMRP values and L/H 
genotypes for each diagnostic group. The statistical significance threshold was set at 0.05 for all the 
analyses, which were performed using GraphPad PRISM 4.0 (San Diego, California, USA). 
ROC curves were generated with MedCalc statistical software (version 12.7.2.0, MedCalc Software, 
Belgium) comparing the non-MPM and MPM groups. First, the ROC curves were calculated without 
taking into account the genotypes. Then the curves were recalculated using SMRP levels of 
alternatively non-MPM volunteers carrying the L (n=374) or H (n=315) genotype, versus the whole 
group of patients with MPM (n=70). In a second analysis, the group with MPM was also stratified by 
L (n=37) and H (n=33) genotype and the ROC curves were repeated. 
 
Construction of plasmids 
The putative human MSLN promoter from nucleotides −1 to−1073 relative to the TSS of RefSeq 
NM_005823.5 was amplified by Q5 high-fidelity DNA polymerase (NEB, Ipswich, USA). 
As template, an individual carrying the common homozygote genotype for all SNPs in the study was 
selected from our sample set. The resultant PCR amplicon was subsequently cloned into the XhoI site 
of the pGL3-basic vector (Promega, Madison, Wisconsin, USA) using CloneEZ PCR Cloning Kit 
(GenScript, Piscataway, USA). This construct, bearing the most common haplotype in the TSI 
population (ie, common allele for every SNP), is from now on referred as ‘pGL3_HAP1’. Subsequent 
site-directed mutagenesis reactions were performed to generate the other haplotype-mimicking 
plasmids with QuikChange II Site-Directed Mutagenesis Kits (Agilent, Santa Clara, California, 
USA). The fidelity of the resulting constructs (pGL3_HAP1/2/3/4) was confirmed by sequencing, 
using the pGL3 external primers (pGL3_F and pGL3_R). The sequence of cloning, mutagenesis, and 
sequencing primers is reported in online supplementary table 1. 
 
Cell culture and luciferase reporter assays 
Non-malignant transformed human pleural mesothelial cells (Met-5A)18 were purchased from ATCC 
(American Type Culture Collection) and cultured in Medium 199 (Gibco in Life Technologies, 
Monza, Italy) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 3 nM 
epidermal growth factor, 400 nM hydrocortisone and 870 nM insulin. Human epithelioid malignant 
mesothelioma cells (Mero-14) were kindly donated by Istituto Tumori of Genova (National Research 
Council, Genova, Italy) and maintained in Dulbecco's modified Eagle’s medium (Lonza, Maryland, 
USA). Met-5A and Mero-14 cells were maintained in a humidified incubator at 37°C in 5% CO2. 
In three independent experiments, Met-5A and Mero-14 cells were seeded in 24-well plates at a final 
density of 50 000 cells/well and incubated for 24 hours. Cells were then co-transfected at 60–80% 
confluence with 400 ng of pGL3_HAP1/2/3/4 and 10 ng of the Renilla pRL-SV40 internal control 
vector (Promega, Madison, USA) using Attractene reagent (Qiagen, Hilden, Germany). Twenty-four 
hours after transfection, a dual-luciferase reporter assay (Promega, Madison, USA) was performed. 
Relative luciferase units (RLU) were expressed as mean value of the firefly luciferase/Renilla 
luciferase ratio of three independent experiments. One-way ANOVA was performed on the RLU 
values to assess statistically significant differences among the four transfected plasmids. Dunnett’s 
multiple comparison tests were performed to assess pairwise differences between the variant vectors 
compared with pGL3_HAP1 plasmid, which carried the most common haplotype (ie, common allele 
for every SNP). Two-way ANOVA was also performed to compare RLU values of the four different 
plasmids among the two cell lines. 
 
RESULTS 
SNPs selection 
In order to identify the genetic variants within MSLN proximal promoter (~1000 bp upstream from 
TSS) to be studied in association with SMRP, we searched for all SNPs significantly associated with 
MSLN mRNA expression in lung tissues on GTex portal (pleural tissues were unavailable). We found 
86 cis-eQTLs with p values ranging from 4.9×10–6 to 4.4×10–33. The region spanning MSLN TSS 
showed the highest associated SNPs. Table 2 lists the top 10 associated SNPs (ie, the SNPs with the 
most significant p value according to GTex) with their main features. Among the 86 associated SNPs, 
we selected those located within the 1000 bp upstream from the TSS—that is, rs3764247 
(16:g.810039 A>C), rs3764246 (16:g.810143 A>G), rs2235503 (16:g.810593 C>A), rs2235504 
(16:g.810655 A>G). Since a strong LD (r2=0.94) was present between rs3764246 and rs2235504, we 
chose rs3764247, rs3764246 and rs2235503 for the genotyping analyses in association with SMRP. 
 
 
 
 
 
 
 
 
 
 
SNP P-value from Gtex Effect size Location Other SNPs in LD 
rs2235503 4.4x10-33 0.98 Promoter (-171 bp from TSS) rs12597489 (r2= 0.8) 
rs2235505 4.1x10-28 0.84 Intron 2 
rs3764246 (r2=0.9) 
rs2235504 (r2=0.92) 
rs9925870 (r2=0.85) 
rs2235504 3.6x10-27 0.81 Promoter (-109 bp a from TSS) 
rs3764246 (r2= 0.94) 
rs2235505 (r2= 0.92) 
rs3764246 7.5x10-27 0.80 Promoter (-621 bp from TSS) 
rs2235504 (r2=0.94) 
rs2235505 (r2=0.9) 
rs12600012 5.6x10-25 0.96 Intron 2 
rs12597489 (r2= 0.85) 
rs3765319 (r2= 0.81) 
rs3764247 7.5x10-25 0.79 Promoter (-724 bp from TSS) - 
rs9925870 2.9x10-24 0.79 Intron 2 rs2235505 (r2= 0.85) 
rs7198927 1.3x10-23 0.94 Promoter (-2593 bp from TSS ) 
rs67623411 (r2= 0.89) 
rs12597489 (r2= 0.88) 
rs12597489 1.5x10-23 0.94 Promoter (-1602 bp from TSS) 
rs67623411 (r2= 0.86) 
rs7198927 (r2= 0.88) 
rs2235503 (r2= 0.8) 
rs12600012 (r2= 0.85) 
rs7185523 8.4x10-22 0.77 Intron 6 rs7185150 (r2= 0.89) 
Table 2. Top ten SNPs in association with MSLN mRNA expression in 278 lung tissues according to GTex portal. For 
each SNP, the P-value of the association and the effect size (i.e. the effect of the alternative allele relative to the reference 
allele on the mRNA expression) according to GTex is reported, together with its position relative to MSLN gene and all 
the SNPs with an r2≤0.8. TSS=transcriptional start site; NM_005823.5 was used as reference.   
Genotyping results in association with SMRP levels in healthy subjects patients with BRD MPM 
As expected, the group of patients with MPM showed a mean serum level of SMRP of 3.58 nM 
(±0.49, SEM), significantly higher than for healthy subjects (0.94±0.03) or patients with BRD 
(1.04±0.03) (ANOVA, p<0.0001). When the SMRP levels were analysed in relation to genotypes for 
each SNP separately, a significant association (overall p values calculated with ANOVA <0.0001) 
was found between SMRP and all the SNPs in the non-MPM category (healthy subjects and patients 
with BRD). As can be seen in table 3 and in figure 1, for each SNP there is an increasing and 
statistically significant trend of SMRP levels in relation to the number of variant alleles carried. This 
trend was observed among healthy individuals and patients with BRD, although the comparison 
between heterozygotes and variant homozygotes was not significant for rs3764247 and rs2235503 in 
the latter group according to Tukey’s multiple comparison test. Interestingly, similar trends were also 
seen in the group of patients with MPM; however, no statistically significant differences were 
achieved for any of the SNPs (p=0.166, 0.363 and 0.373 for rs3764247, rs3764246 and rs2235503, 
respectively), probably owing to low statistical power when comparing subgroups of patients with 
MPM. In order to ascertain the global role of these SNPs, we used the three-SNPs classifier assigning 
the H or L genotype for each volunteer of this study. Then, a mANOVA was employed with ‘health 
status’ and ‘classifier’ as independent factors. This model confirmed that SMRP levels were 
associated with the promoter genotype (L vs H, p=0.001) and diagnosis (non-MPM vs MPM 
p<0.0001). Moreover, the interaction between these factors was not statistically significant (p=0.373), 
given that among patients with MPM the group carrying the L genotype also showed an average 
SMRP lower than the patients carrying the H genotype (however, the difference between H and L 
genotype within patients with MPM was not statistically significant). When SMRP was evaluated as 
a biomarker regardless of the genotype information, the ROC curves showed an area under the curve 
(AUC) of 0.867 (95% CI 0.841 to 0.890). The Youden’s J index (0.566) pointed at the SMRP cut-off 
value of 1.28 nM, resulting in a sensitivity of 76.7% and a specificity of 79.9%. At a cut-off value of 
1 nM (as suggested in previous works),16 19 the sensitivity rose to 87.7%, but the specificity dropped 
to 64.1%. When considering the genotypes, in a first analysis, non-MPM subjects were stratified by 
L (n=374) or H (n=315) promoter status, whereas patients with MPM were considered as a whole. In 
fact, their SMRP levels did not associate with genotypes in a statistically significant way and their 
stratification might have led to a reduction of the statistical power of the analysis. The distributions 
of these SMRP values are reported in online supplementary figure 1. In the ROC curves, the lowest 
rates of false-positive results were obtained among non-MPM subjects carrying the L promoter, 
where Youden’s J index rose to 0.690 (at 1.11 nM), the AUC to 0.922 and the sensitivity and 
specificity to 83.6% and 85.5%, respectively. ROC curves calculated for non-MPM individuals with 
the H promoter showed a worse performance, with AUC of 0.801 and a decrease of specificity to 
67% corresponding to Youden’s J index (1.28 nM). 
Online supplementary figure 2 A-B-C reports these ROC curves, whereas online supplementary table 
2 reports the values of sensitivities and specificities for each group. The different cut-off values with 
their corresponding sensitivity and specificity for L and H groups are reported in online 
supplementary tables 3 and 4. A second analysis was attempted by stratifying both non-MPM and 
MPM volunteers for L and H genotypes, despite the small number of patients with MPM falling in 
the two genotypic groups (37 and 33, respectively). In the ROC curves, the lowest rates of false-
positive results were again obtained among subjects carrying the L promoter, where Youden’s J index 
pointed at an optimal cut-off value of 1.11 nM, the AUC to 0.914 and the sensitivity and specificity 
to 79.5% and 85.5%, respectively. ROC curves calculated for individuals with the H promoter showed 
a worse performance for SMRP, with AUC of 0.829 and a decrease of specificity to 67%, in 
correspondence with Youden’s J index (1.28 nM). These ROC curves are reported in online 
supplementary figure 2B,C (right panel) in parallel with the curves obtained without stratifying the 
MPM group according to the promoter genotype (left panel). 
SNP Healthy subjects (371) BRD subjects (318) MPM subjects (70) 
rs3764247 
AA 0.76±0.03 (237, 64%) AA 0.92±0.04 (213, 67%) AA 3.33±0.60 (46, 66%) 
AC 1.20±0.05 (119, 32%) AC 1.29±0.06 (95, 30%) AC 3.17±1.10 (18, 26%) 
CC 1.75±0.13 (15, 4%) CC 1.62±0.19 (10, 3%) CC 6.78±1.74 (6, 8%) 
rs3764246 
AA 0.73±0.03 (214, 58%) AA 0.88±0.04 (193, 61%) AA 3.14±0.66 (39, 56%) 
AG 1.11±0.04 (136, 37%) AG 1.25±0.06 (109, 34%) AG 3.77±0.82 (26, 37%) 
GG 1.86±0.10 (21, 5%) GG 1.80±0.14 (16, 5%) GG 5.97±1.91 (5, 7%) 
rs2235503 
CC 0.76±0.03 (268, 72%) CC 0.91±0.04 (240, 75%) CC 3.23±0.59 (51, 73%) 
CA 1.29±0.05 (94, 25%) CA 1.45±0.07 (72, 23%) CA 4.05±1.07 (15, 21%) 
AA 2.20±0.15 (9, 3%) AA 1.82±0.24 (6, 2%) AA 6.15±2.13 (4, 6%) 
Table 3. SMRP values for each genotype in each health-status group. The values are reported as mean (nM) ± standard 
error (SEM). Absolute numbers and percentages are given in brackets. 
 
In vitro study on the SNPs located within the MSLN promoter reported a functional role for 
rs3764247 
In order to elucidate the biological role of the SNPs found to be associated with SMRP, an in vitro 
study was performed cloning the putative promoter region of MSLN (−1 to −1073 relative to the TSS) 
upstream from a reporter gene. We then applied site-directed mutagenesis to obtain the most common 
haplotypes present in the population, since we reasoned that the functional role of SNPs should be 
investigated in a genetic environment that allows SNP-to-SNP interactions as they are likely to 
happen physiologically. The four most common haplotypes in the TSI/CEU population according to 
Haploview are rs3764247(A)–rs3764246(A)–rs2235503(C)–rs2235504(A) (HAP1, 71%) (common 
allele for all SNPs), rs3764247(C)–rs3764246(G)–rs2235503(A)–rs2235504(G) (HAP2, 15%) 
(variant allele for each SNP), rs3764247(A)–rs3764246(G)–rs2235503(C)–rs2235504(G) (HAP3, 
8%) (variant allele for second and fourth SNP), rs3764247(C)–rs3764246(A)–rs2235503(C)–
rs2235504(A) (HAP4, 4%) (variant allele for the first SNP). Therefore, we obtained four plasmids 
(pGL3_HAP1/2/3/4) carrying the above SNP sequence and used a luciferase assay to study the 
activity of the promoter. The vectors were transfected into Met-5A and Mero-14 cells and the reporter 
activity under the control of promoters bearing different genetics variants was evaluated. 
In comparison with pGL3_HAP1 (set at 100%,±4% SEM), RLU values of pGL3_HAP2, 
pGL3_HAP3 and pGL3_HAP4 were 121% (±8%), 97% (±12%) and 182% (±18%) in Met-5A, 
respectively (figure 2A). In Mero-14 these values were 194% (±19%), 153% (±34%) and 191% 
(±34%), as shown in figure 2B. A significant difference in RLU (overall p value calculated with 
mANOVA <0.0001) was found among the constructs in both cell lines, whereas the interaction 
between haplotypes and cell lines was not statistically significant (p interaction=0.185), suggesting 
that the constructs gave similar responses in both cell lines (summarised in figure 2C). The Dunnett’s 
pairwise comparisons showed that in both cell lines pGL3_HAP2 was higher than pGL3_HAP1 (p 
values of 0.064 and 0.028 in Met-5A and Mero-14, respectively), pGL3_HAP3 was not statistically 
different from pGL3_HAP1 (p=0.221 and 0.358), whereas pGL3_HAP4 led to the highest RLU 
signal (p=0.0031 and 0.034 in comparison with pGL3_HAP1). The statistically significant 
differences compared with pGL3_HAP1 are shown in figure 2 marked with an asterisk. 
 
Discussion 
MSLN is a membrane glycoprotein described as functionally involved in many malignancies, 
including MPM. It has been repeatedly reported that measurement of the levels of its soluble form 
(SMRP) might help to discriminate between patients with MPM and non-MPM subjects, although its 
performance is limited by high rates of false-positive and false-negative results.11 Regulatory SNPs 
within promoters play an important role in various diseases, including cancer,20–22 myocardial 
infarction23 and diabetes.24 In this study, we aimed at broadening our knowledge of the biological 
role played by genetic variants located within MSLN promoter region, with potential impact also on 
the performance of SMRP as a diagnostic biomarker. Thus, we selected four SNPs (rs3764247 A>C, 
rs3764246 A>G, rs2235503 C>A, rs2235504 A>G) within 1000 bp upstream from the MSLN TSS 
and, in the first part of the study, we investigated the association between SMRP and genetic variants 
in over 700 individuals, assigning reliability against possible chance findings. Although post-
transcriptional and post-translational regulatory mechanisms (such as alternative splicing, 
microRNAs and proteolytic cleavage) could impair the correlation between MSLN mRNA and its 
product SMRP, we found significant associations between genotypes and SMRP levels, in agreement 
with those reported in the cis-eQTL database within the GTex portal. The genotype, together with 
other confounders,13 14 contributes to the wide interindividual variations commonly found in serum 
SMRP levels.11 Considering the global effect of these SNPs (summarised in the L/H classifier), 
different sensitivities and specificities were found when SMRP was employed as a biomarker. The 
inclusion of the genotype in the calculation of ROC curves led to an improved diagnostic 
performance, with the lowest rate of false-positive results in individuals carrying the L genotype, 
implying that high levels of SMRP could be more worrying for people carrying this genotype. In 
surveillance screening, information about the genotype could be helpful in interpreting the SMRP 
measurement, as shown by data from ROC curves, where both clinical groups were stratified by L/H 
genotype. 
 
In the second part of the study, we found that the genotype-dependent levels of SMRP paralleled, at 
least partially, the results obtained in vitro, where the functional role of naturally occurring haplotypes 
was evaluated. Overall, a direct effect of rs3764247 was suggested by the higher expression of 
pGL3_HAP4 and pGL3_HAP2 in comparison with pGL3_HAP1; further studies are needed to 
ascertain its role in MSLN regulation. HaploReg v4 (www.broadinstitute.org/mammals/haploreg) 
showed that this SNP is located in DNase I hypersensitive sites (DHSs) in neuronal progenitors and 
astrocyte primary cells. According to RegulomeDB (http://www.regulomedb.org/), it lies within 
enhancer regions in lung tissues and it is suggested that it affects binding sites for two transcription 
factors, namely Staf and ZNF143. Thus future research could be directed towards the experimental 
validation of these interactions in mesothelial cells. Moreover, according to the luciferase assay, 
rs3764246 and rs2235504 are unlikely to play a direct role in MSLN regulation, as suggested by the 
similar expression of pGL3_HAP3 and pGL3_HAP1. Because these two SNPs were found associated 
with in vivo SMRP levels and with MSLN mRNA (as cis-eQTL within the GTex database), a 
different mechanism should be evoked. A SNP in strong LD with them might be responsible for these 
observations. Rs2235505, located within intron 2 of the MSLN gene, has an r2=0.92 with rs2235504 
and r2=0.9 with rs3764246. Moreover, this intronic SNP is listed in GTex as cis-eQTL of MSLN 
mRNA, and functional annotations reported its localisation in DHSs in HeLa and HepG2 cell lines 
and its ability to affect several transcription factor binding motifs such as BHLHE40, CTCF, PLAG1 
and Rad21. It was also shown to bind RCOR1 chromatin binding protein in HeLa cells. Thus, 
rs2235505 might be worth further investigation, including an in vitro study to assess whether it might 
be the functional SNP responsible for the in vivo observed associations. A visual summary of the 
results of the functional study on the MSLN promoter is reported in Supplementary Figure 3. 
 
Beside the potential location of the SNPs in DHSs, other regulatory mechanisms could be affected 
by single nucleotide variations. SNPs located within CpG islands in the promoter were previously 
shown to affect expression of the neighbour mRNA and eventually, to be associated with the 
pathological condition.25 26 In MPM, a clear hypomethylation of MSLN promoter was observed by 
Tan and coauthors27 and interestingly, Nelson and collaborators found an association between MSLN 
promoter hypomethylation and high levels of SMRP in patients with MPM.28 Therefore, it is 
reasonable to suggest that SNPs located in the MSLN promoter within a CpG island could affect the 
methylation status and ultimately, the SMRP levels. Nonetheless, the SNPs analysed in this study do 
not fall within the region examined by the Nelson or Tan research groups, thus their role in epigenetic 
regulation would need to be further explored. 
 
Interestingly, our evidence of association between genetic variants and biomarker levels is 
reminiscent of previous observations concerning SNPs lying within the PSA (prostate-specific 
antigen) gene promoter.29 These SNPs were shown to contribute to individual differences among 
healthy men in the levels of serum PSA, a common biomarker for prostate cancer.29 This reinforces 
the need to make use of the genetic information when considering specific biomarkers in surveillance 
programmes. Interestingly, we noticed that, as seen in non-MPM volunteers, patients with MPM rare 
homozygotes had the highest average levels of SMRP, whereas heterozygotes showed intermediate 
levels. However, these trends, and the difference between H and L genotypes, were not statistically 
significant. We investigated whether this could be due to an association between tumour histology 
and genotypes (since SMRP is more frequently elevated in the epithelioid subtype), but no relation 
was found (data not shown). Therefore, we hypothesised that the lack of statistical significance might 
be ascribed to the relatively small number of patients with MPM recruited to this study. This 
hypothesis was supported by a post hoc power analysis (data not shown) and by the positive results 
we obtained in luciferase assays in MPM Mero-14 cells. We could not gather together more patients, 
as MPM is a rare disease, but it is likely that among patients the increase of SMRP might be more 
evident among carriers of the H genotype. 
 
In conclusion, we reported that SMRP levels are affected by genetic variants, resulting in different 
‘warning’ thresholds for healthy subjects carrying different genotypes. A challenging aspect of the 
biomarker study would be the identification of SNPs explaining the presence of false-negative 
results—that is, low SMRP levels among patients with MPM. The recruitment of a larger sample of 
patients with MPM would be required for this purpose. The present work suggested that some of 
these SNPs have a functional role and this needs further investigation. These analyses could help in 
understanding the biological mechanisms of transcriptional regulation of the MSLN gene and 
eventually contribute to explaining the high levels of this protein in MPM, shedding some light also 
on the mechanisms of pleural carcinogenesis. 
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FIGURE LEGENDS 
Figure 1. Association between genetic variants within the MSLN promoter (i.e. rs3764247, 
rs3764246 and rs2235503) and SMRP levels in healthy (A), BRD (B) and MPM (C) subjects. In the 
figure key, “AA” indicate subjects carrying the common homozygote genotype, “Aa” the 
heterozygotes, “aa” the variant homozygotes. Asterisks show a statistical significance (P < 0.05) in 
the Tukey’s test for pairwise differences within the ANOVA model. The columns represent mean 
values, the bars show standard error of the mean (SEM). 
 
Figure 2. In each panel the different haplotype constructs of MSLN promoter (left) and dual-
luciferase reporter assays results (right) are reported. Left: diagram of four promoter constructs 
showing four different haplotypes. The number indicates the relative nucleotide position of the four 
SNPs from the TSS. Right: luciferase activity was presented as the ratio between the firefly/Renilla 
luciferase values (RLU). RLU measured after pGL3_HAP1 transfection is reported as 100% and used 
as reference for statistical evaluation. Asterisks show a statistical significance (p<0.05) in the Dunnett 
test for pairwise differences within the analysis of variance (ANOVA) model between 
pGL3_HAP2/3/4 and the reference pGL3_HAP1 in panels A and B. Asterisks show a statistical 
significance (p<0.05) in the Sidak test for pairwise differences within the multivariate ANOVA model 
between pGL3_HAP2/3/4 and the reference pGL3_HAP1 in panel C. The columns represent mean 
values, the bars show the standard error of the mean (SEM). MPM, malignant pleural mesothelioma; 
SNPs, single nucleotide polymorphisms; TSS, transcriptional start site. 
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